Evidence map›Paper›PMID 39476535›Full record

ArticleEBioMedicine2024

Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.

Li Song, Chunyan Zhu, Qing Shi, Yuhan Xia, Xiayi Liang, Wen Qin, Tao Ye, Biwei Yang, Xin Cao, Jinglin Xia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A Comprehensive Review on Anticancer Potential ofCurrent cancer drug targets · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li SongNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Chunyan ZhuCentral Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu, 610072, Sichuan, China; Department of Stomatology and Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, No. 301 Yanchangzhong Road, Shanghai, 200072, China.
Qing ShiDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, No. 2, Xuefu Lane, Wenzhou, 325000, Zhejiang, China.
Yuhan XiaDepartment of Oncology, Minhang Branch, Zhongshan Hospital, Fudan University, No. 170, Shensong Road, Shanghai, 200032, China.
Xiayi LiangCentral Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu, 610072, Sichuan, China.
Wen QinCentral Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu, 610072, Sichuan, China.
Tao YeDepartment of Oncology, Minhang Branch, Zhongshan Hospital, Fudan University, No. 170, Shensong Road, Shanghai, 200032, China.
Biwei YangNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Xin CaoInstitute of Clinical Science, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China. Electronic address: caox@fudan.edu.cn.
Jinglin XiaNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, No. 2, Xuefu Lane, Wenzhou, 325000, Zhejiang, China. Electronic address: xiajinglin@fudan.edu.cn.
Kun ZhangCentral Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Second Section, First Ring Road, Chengdu, 610072, Sichuan, China. Electronic address: zhang1986kun@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent embolic agents in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) encounter instability and easy leakage, discounting TACE efficacy with residual HCC. Moreover, clinical TACE aggravates hypoxia and pro-metastatic microenvironments, rendering patients with HCC poor prognosis.

methodsHerein, we developed Zein-based embolic agents that harness water-insoluble but ethanol-soluble Zein to encompass doxorubicin (DOX)-loaded mesoporous hollow MnO

findingsThe high adhesion and crosslinking of Zein with HMnO

interpretationThis innovative work not only provides a new TACE agent for HCC, but also establishes a new strategy to ameliorate TACE-aggravated hypoxia and metastasis motivation against clinically-common HCC metastasis after TACE operation.

fundingExcellent Young Science Fund for National Natural Science Foundation of China (82022033); National Natural Science Foundation of China (Grant No. 82373086, 82102761); Major scientific and technological innovation project of Wenzhou Science and Technology Bureau (Grant No. ZY2021009); Shanghai Young Top-Notch Talent.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinLiver NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionHumansMiceRabbitsReactive Oxygen SpeciesXenograft Model Antitumor AssaysZeinDoxorubicinReactive Oxygen SpeciesZeinGlycometabolismHepatocellular carcinomaHypoxia mitigationPro-metastatic microenvironment inhibitionTranscatheter arterial chemoembolization (TACE)Zein-based embolic agents

Identifiers

PMID39476535
PMCPMC11567102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.